

NCCN Thymomas and Thymic Carcinomas Guidelines V.1.2012 – Meeting – 06/17/11

Guideline Page and Request	Panel Discussion	References	Vote		
			Yes	No	Abstain
<p>THYM-4 Internal request: Suggest adding the category of isolated solitary metastasis with treatment recommendations.</p>	<p>The panel consensus was to add the category of isolated solitary metastasis. This resulted in adding chemotherapy as an initial treatment option, followed by additional chemotherapy in combination with RT if the patient is deemed unresectable at surgical re-evaluation. Chemotherapy was also added as an option after initial treatment with surgery</p>	<ul style="list-style-type: none"> • Loehrer, PJ et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an Intergroup trial. <i>J Clin Oncol</i> 1994; 12:1164, • Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: a final report. <i>Lung Cancer</i> 2004;44:369-79. • Fornasiero, A et al. Chemotherapy for invasive thymoma. A 13-year experience. <i>Cancer</i> 1991;68:30. • Giaccone, G et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. <i>Journal of Clinical Oncology</i> 1996;14:814. • Loehrer PJ Sr, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. <i>Cancer</i> 2001; 91: 2010–5. • Lemma GL, Lee JW, Aisner SC, et al. A phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. <i>J Clin Oncol</i> 2011;29:2060-2065. 	29	0	0
<p>THYM-C Internal request: Add the long acting formulation of octreotide as a treatment option in second-line therapy.</p>	<p>The panel consensus was to add the octreotide LAR formulation as an option in second-line therapy.</p>	<ul style="list-style-type: none"> • Loehrer PJ Sr, Wang W, Johnson DH, et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. <i>J Clin Oncol.</i> 2004;22:293-299. • Ito J, Sekiya M, Miura K, et al. Refractory recurrent thymoma successfully treated with long-acting somatostatin analogue and prednisolone. <i>Intern Med.</i> 2009;48:1061-1064. • Longo F, De Filippis L, Zivi A, et al. Efficacy and Tolerability of long-acting Octreotide in the Treatment of Thymic Tumors: Results of a Pilot Trial. <i>Am J Clin Oncol.</i> 2011 Feb 15. [Epub ahead of print] 	29	0	0